Anagliptin
Anagliptin has been studied in 3 papers since 2017: none in people yet, 2 in animals, 1 in cells; 1 in the past year. The research so far is in animals and cells. The newest paper, Feb 3, 2026: “Endogenous GIP signaling is indispensable for DPP-4 inhibitor-mediated metabolic control in mice”.
See all 4 papers on anagliptin
At a glance
The findings reach mice, none yet in people. 2 independent labs in 3 countries; 3 trials, 2 about aging, 2 with no results posted.
None of its findings points the other way.
- 2 independent labs in 3 countries
- 3 trials, 2 about aging, 2 with no results posted
- Funders: Government of Japan Ministry of Education Culture Sports Science and Technology and 3 more
- 3 of 3 trials sponsored by its developers
- Animals2
- Cells1
What did studies of anagliptin find?
5Studies of anagliptin measured 5 outcomes, among them telomerase activity, inflammatory cytokine secretion and SIRT1.
Telomerase activity
upin cells1
1 study
Telomerase activity
upin cells1
Anagliptin increases telomerase activity in IL-1β-exposed cells (20.3 and 24.6 IU/L with 2.5 and 5 μM Anagliptin, versus 15.8 IU/L with IL-1β alone).
“exposure to IL-1β reduced telomerase activity from 26.7 IU/L to 15.8 IU/L, which was increased to 20.3 and 24.6 IU/L by 2.5 and 5 μM Anagliptin”
Cellsin IL-1β-exposed cellsvascular smooth muscle cells2.5 and 5 μM
Bioengineered
Inflammatory cytokine secretion
downin cells1
1 study
Inflammatory cytokine secretion
downin cells1
Anagliptin decreases inflammatory cytokine secretion in cells.
“Anagliptin treatment ameliorated the elevated secretions of tumor necrosis factor-α (TNF-α), interleukin 6 (IL-6), and macrophage chemoattractant protein-1 (MCP-1).”
Cellsvascular smooth muscle cells
Bioengineered
SIRT1
upin cells1
1 study
SIRT1
upin cells1
Anagliptin increases SIRT1 in IL-1β-treated cells.
“Anagliptin dramatically reversed the upregulated p16, p21, and downregulated sirtuin1 (SIRT1) in IL-1β-treated vascular smooth muscle cells.”
Cellsin IL-1β-treated cellsvascular smooth muscle cells
Bioengineered
Cellular senescence
downin cells1
1 study
Cellular senescence
downin cells1
Anagliptin protects against cellular senescence in cells (IL-1β-induced senescence) (SA-β-galactosidase staining reduced from 3.1-fold to 2.3- and 1.6-fold of control, dose-dependently).
“Anagliptin protects vascular smooth muscle cells from cytokine-induced senescence”
CellsIL-1β-induced senescencevascular smooth muscle cells
Bioengineered
Atherosclerotic lesion formation
downin mice1
1 study
Atherosclerotic lesion formation
downin mice1
Anagliptin decreases atherosclerotic lesion formation in mice under chronic stress in ApoE-/- mice.
“DPP4 inhibition with anagliptin reversed stress-related atherosclerotic lesion formation”
Animalsunder chronic stress in ApoE-/- miceaortic root
International journal of cardiology
Has anagliptin been tested in people?
2 of 3 about agingNo study of it in people has been published yet.
Trial sponsors
Company2 trialsPhase 4378 people